Aug 2026· Gene Therapy· Vol 33, pp. 505 - 514· 0 citations· 35 references
Medicine
TL;DR
It is demonstrated that engineering the required helper gene expression can greatly increase AAV production relative to the use of native adenovirus gene regulation, and two different engineered helper plasmids improved AAV vector genome (VG) titers up to 5-fold compared to a standard helper plasmid.
Abstract
Helper plasmids that depend on native adenovirus gene expression have long been the standard for transient adeno-associated virus (AAV) production. Here, we demonstrate that engineering the required helper gene expression can greatly increase AAV production relative to the use of native adenovirus gene regulation. Two different engineered helper plasmid designs improved AAV vector genome (VG) titers up to 5-fold compared to a standard helper plasmid. A substantial decrease in adenovirus E4orf6 and an increase in L4 22K and 33K gene expression were associated with the improved engineered helper plasmids. VG titer improvement across capsid serotypes, plasmid transfection platforms and genome designs suggest that engineering helper gene expression is widely suited to improving AAV manufacturing yields while also maintaining consistent vector quality attributes.
Recombinant adeno-associated virus (rAAV) vectors have emerged as leading platforms for gene therapy owing to their safety, long-term transgene expression, and broad tissue tropism. However, rAAV production in HEK293 cells via triple-plasmid transfection remains limited by low yield, partly due to inefficient nuclear i...
He Ren, Jian-Qi Nie, Zi-Chuan Song et al.· Biotechnology Journal· 0 citations
A 140% increase in pHelper plasmid production is reported, while the most successful ITR variant increased pTransgene plasmid yields by 57% and transgene expression by 28%, without reducing rAAV yields or transduction efficiency.
Nicholas Donohue, Alexandra Bogdanovic, James Conheady et al.· International Journal of Mol...· 0 citations
Recombinant vectors derived from adeno-associated viruses (rAAVs) are a mainstay of human gene therapy. rAAVs are produced from plasmids containing transgene cassettes flanked by inverted terminal repeats (ITRs), which form structured DNA elements that stabilize the ends of the single-stranded viral genome and are the...
A CD7-targeted rAAV vector featuring a nanobody-fused hybrid capsid derived from a rationally selected chimeric combination of AAV6 and AAV9 establishes an integrated capsid-genome design framework for targeting human T and NK cells, notoriously challenging immune cell populations for gene therapy, and provides a versa...
H. Jahnz, M. V. Hamann, Hongil Kim et al.· Human Gene Therapy· 0 citations
This protocol enables quantification of INDELs and DNA-SVs, allowing for validation of gene disruption, and describes guide RNA (gRNA) design, plasmid cloning, delivery of AAV-CRISPR to the liver, and execution of liver DNA-editing analysis.
K. Jarrett, Rodrigo Baltazar-Nunez, Chloe Anne Borja et al.· STAR Protocols· 0 citations
The history and evolution of various baculovirus systems for rAAV production are outlined and the most modern and promising platforms for assembling recombinant AAV particles are described.
O. V. Orlova, D. Glazkova, O. N. Sidorova et al.· Molecular Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.